RxDoctor Payments Data

Jennifer Garrison, APRN

Family · Bridgeton, NJNPI 1477339232

Payments from drug & device makers

$255in general payments, 2019–2025

Across 9 payments — averaging $28.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$126
  • GSK$49
  • AstraZeneca$30
  • Amgen$19
  • Lilly USA, LLC$17
  • Pfizer$15

What the payments were for

  • Food & beverage$255100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic1$126
GSK3$49
AstraZeneca2$30
Amgen1$19
Lilly USA, LLC1$17
Pfizer1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$255 in reported general payments places this provider in the 45th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$112,940
Medicare patients
344
Services billed
1,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin51$24,507
EliquisApixaban40$15,360
OzempicSemaglutide13$12,746
XareltoRivaroxaban23$7,013
FarxigaDapagliflozin Propanediol13$3,853
Levemir FlexpenInsulin Detemir31$3,575
MyrbetriqMirabegron15$2,832
Insulin Aspart FlexpenInsulin Aspart37$1,964
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro11$1,947
Levothyroxine Sodium124$1,937
Tresiba Flextouch U-100Insulin Degludec16$1,867
Humalog Kwikpen U-100Insulin Lispro26$1,758
LokelmaSodium Zirconium Cyclosilicate19$1,754
Divalproex Sodium38$1,744
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$1,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$15,36040 claims
AstraZenecaFarxiga, Lokelma$30$5,60732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,692 family providers in New Jersey.

Other family in Bridgeton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →